database / melanocortin

Melanotan II

research compound melanocortin integumentarynervousendocrine sequence not characterised

74 heavy atoms · 147 bonds · drag to pan, scroll to zoom C50N15O9

Skeletal structure drawn from the computed atomic coordinates in PubChem CID 92432. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 — a lactam-cyclised peptide with norleucine and D-phenylalanine.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formula	C50H69N15O9
molecular weight	1024.2 Da (PubChem)
computed backbone mass	not characterised
length	not characterised
net charge (pH 7.4)	not characterised
mean hydropathy	not characterised
half-life	not characterised
delivery route	not characterised
PubChem CID	92432
PDB	not characterised
UniProt parent	not characterised

Mechanism

Non-selective melanocortin receptor agonist.

Reported targets: MC1R MC3R MC4R

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcome	where it appears
melanogenesis	Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Repor… Life (Basel, Switzerland) 2026
appetite effects in models	Melanotan II nasal spray: a possible risk factor for oral mucosal malignant … International journal of oral and maxillofacial surgery 2025
sexual-function effects in trials	Barbie drug identification: Not a child's play Journal of forensic sciences 2024

Registered trials

Records from ClinicalTrials.gov. Listed for reference — this project sponsors no trial and is not involved in any of them.
NCT	title	status	phase
NCT07437560	Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonse	RECRUITING	PHASE2

Literature (8)

Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report — Life (Basel, Switzerland) 2026

This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect. Melanotan II is an unlicensed synthetic peptide analog belonging to the melanocortin hormone family. It acts primarily by activating melanocortin 1 receptors on melanocytes, stimulating eumelanin production and resulting in skin pigmentation independent of sun exposure. Despite its popularity, particularly through promotion on social media, Melanotan II remains unregulated, and its use is associated with a range of potential adverse effects. During the initial intraoral examination, brown pigmentation was observed on the attached gingiva in both the maxillary and mandibular arches. The lesions were almost symmetrically distributed, with a more intense coloration in the anterior region of the lower jaw. Ad…

open access ↗ · PMID 41752902 · DOI 10.3390/life16020265

Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? — International journal of oral and maxillofacial surgery 2025